Enterprise Value
229.3B
Cash
11.93B
Avg Qtr Burn
N/A
Short % of Float
0.98%
Insider Ownership
0.05%
Institutional Own.
68.23%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LITFULO™ (Ritlecitinib) Details Alopecia areata | Approved Update | |
Zavzpret (Zavegepant) Details Migraines | Approved Update | |
TALA + enzalutamide Details Cancer, Prostate cancer, Castration-resistant prostate cancer | Approved Update | |
Approved Quarterly sales | ||
BRAFTOVI + MEKTOVI Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
BEQVEZ™ (fidanacogene elaparvovec-dzkt) Details Hemophilia, Hemophilia B | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
PADCEV® Details Urothelial carcinoma | Approved Quarterly sales | |
ADCETRIS® (Brentuximab Vedotin) Details Hodgkin Lymphoma | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Cancer, Metastatic colorectal cancer, Colorectal cancer | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
PREVNAR 20 (20-valent pneumococcal conjugate vaccine) (20vPnC) Details Invasive pneumococcal disease | Approved Quarterly sales | |
ELREXFIO (elranatamab) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
LORBRENA® Details Cancer, Lung cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
PENBRAYA Details Meningitis | Approved Quarterly sales | |
ABRYSVO Details Respiratory syncytial virus, Respiratory virus | Approved Quarterly sales | |
Oxbryta (Voxelotor) Details SCD (Sickle Cell Disease) | Approved Quarterly sales | |
PADCEV® + KEYTRUDA® (pembrolizumab) Details Bladder cancer | Approved Quarterly sales | |
Bivalent Respiratory Syncytial Virus (RSV) Vaccine /RSVpreF (Older adults) Details Respiratory syncytial virus, Respiratory virus | Approved Quarterly sales | |
Paxlovid Details COVID-19 | Approved Quarterly sales | |
VELSIPITY Details Ulcerative colitis | Approved Quarterly sales | |
Marstacimab Details Hemophilia | PDUFA Approval decision | |
Aztreonam-Avibactam (ATM-AVI) Details Pneumonia, Bacterial infection, Intra-abdominal infections | NDA Submission | |
modFlu mRNA Vaccine /PF-07252220 Details Influenza | Phase 3 Data readout | |
Inclacumab (P-selectin inhibitor) Details Sickle cell disease | Phase 3 Data readout | |
IBRANCE (palbociclib) Details Cancer, Breast cancer | Phase 3 Data readout | |
Phase 3 Update | ||
TUKYSA (Tucatinib) combo Kadcyla Details Cancer, Solid tumor/s, Breast cancer | Phase 3 Update | |
Troriluzole Details Obsessive compulsive disorder | Phase 2/3 Data readout | |
Danuglipron Details Obesity, Type 2 diabetes | Phase 2b Update | |
PF-07940367 (GBT021601) Details Sickle cell disease | Phase 2 Data readout | |
ADCETRIS® + pembrolizumab Details Solid tumor/s, Melanoma, Non-small cell lung carcinoma | Phase 2 Data readout | |
Ponsegromab Details Cancer, Cancer cachexia | Phase 2 Data readout | |
Verdiperstat Details Multiple System Atrophy | Failed Discontinued | |
Verdiperstat Details Amyotrophic lateral sclerosis | Failed Discontinued | |
Troriluzole Details Alzheimer's disease | Failed Discontinued | |
Failed Discontinued | ||
Troriluzole Details Spinocerebellar Ataxia | Failed Discontinued |